ABIVAX Société Anonyme (AAVXF)

Market Cap	6.17B
Revenue (ttm)	7.07M
Net Income (ttm)	-229.46M
Shares Out	n/a
EPS (ttm)	-3.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	74
Open	86.10
Previous Close	86.10
Day's Range	86.10 - 86.10
52-Week Range	5.81 - 88.90
Beta	0.13
RSI	75.68
Earnings Date	Dec 15, 2025

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 69
• Stock Exchange: OTCMKTS
• Ticker Symbol: AAVXF

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.

Financial numbers in EUR